News

DSM enters algae alliance
Enlarge image

BusinessFranceGermany

DSM enters algae alliance

12.10.2012 - Dutch Royal DSM collaborates with a Sanofi subsidiary to stretch ist algal expression system into animal health vaccine production.

This strategic alliance could change the established ways of vaccine production. DSM Nutritional Product, a subsidiary of Dutch Royal DSM N.V., has announced a Development and Option to License Agreement with animal health specialist Merial Limited, part of the US-subsidiary of French Sanofi S.A. The partners want to bring together their expertise to produce animal health vaccines in DSM’s proprietary algal expression system. Compared to existing techniques based on eggs or cell cultures, the new platform could present a faster and more efficient production method. Financial details were not disclosed. It is known, however, that Merial will provide R&D funding to value DSM’s research efforts. DSM would also be eligible to receive milestone payments, license fees and royalties on sales of a successfully launched product.

Almost two years ago Royal DSM acquired Martek Biosciences Corporation from Columbia (Maryland, USA) in a billion dollar deal. This marked DSM’s transformation into a life sciences and materials sciences company. In Columbia omega-3- and omega-6-products are produced by algae. Former Martek CEO Peter Nitze, now President of the Nutritional Lipids division of DSM Nutritional Products, welcomes the expansion of the algae-production portfolio: „We are pleased to join Merial on this important project that we expect will validate the algal expression system as a viable alternative to known vaccine production methods.“ DSM is better known as a global player in biofuel production. The company hit the news earlier this year when it announced the start of a joint venture with US-ethanol producer POET, LLC.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/dsm-wants-algae-made-vaccines.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%

TOP

  • NORDIC NANOVECTOR (N)34.50 NOK40.8%
  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • GW PHARMACEUTICALS (UK)514.61 GBP-13.6%
  • WILEX (D)1.46 EUR-13.6%

TOP

  • NICOX (F)10.29 EUR441.6%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK83.4%

FLOP

  • BB BIOTECH (D)44.30 EUR-83.1%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.65 SEK-75.4%

No liability assumed, Date: 29.08.2016